Tumour lysis syndrome: Implications for cancer therapy

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3555-3560

  Mika, Denish ^a   Ahmad, Sabrina ^a   Guruvayoorappan, C ^a  

^a KARUNYA UNIVERSITY   (India)

Author keywords

Clinical manifestations; Hyperkalemia; Management; Tumour lysis syndrome

Indexed keywords

EID: 84873627107     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3555     Document Type: Short Survey

References (54)

1. Annemans L, Moeremans K, Lamotte M, et al. (2003). Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma, 44, 77-83.
2. Arrambide K, Toto RD (1993). Tumor lysis syndrome. Semin Nephrol, 13, 273-80.
3. Band PR, Silverberg DS, Henderson JF, et al. (1970). Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med, 283, 354-7.
4. Bosly A, Sonet A, Pinkerton CR, et al. (2003). Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer, 98, 1048-54.
5. Cairo MS, Bishop M (2004). Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol, 127, 3-11.
6. Cairo M S, Coenelis M, Baruchel A, et al. (2007). Risk assessment and medical decision model for prophylaxis and treatment of hyperuricemia and tumor lysis syndrome (TLS): international expert panel analysis. J Clin Oncol, 25, 17006.
7. Cammalleri L, Malaguarnera M (2007). Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci, 4, 83-93.
8. Cheson B D, Dutcher B S (2005). Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol, 3, 117-24.
9. Conger J D, Falk S A, Guggenheim S J, Burke T J (1976). A micropuncture study of the early phase of acute urate nephropathy. J Clin Invest, 58, 681-9.
10. Coiffier B, Mounier N, Bologna S, et al. (2003). Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol, 21, 4402-6.
11. Davidson M B, Thakkar S, Hix J K, et al. (2004). Pathophysiology, clinical consequences and treatment of tumour lysis syndrome. Am J Med, 116, 546-4.
12. DeConti R C, Calabresi P (1966). Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med, 274, 481-6.
13. Del Toro G, Morris E, Cairo M S (2005). Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin Adv Hematol Oncol, 3, 54-61.
14. Drakos P, Bar-Ziv J, Catane R (1994). Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol, 17, 502-5.
15. Fleming D R, Doukas M A (1992). Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma, 8, 315-8.
16. Goldman S C, Holcenberg J S, Finklestein J Z, et al. (2001). A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 97, 2998-3003.
17. Hande K R, Garrow G C (1993). Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med, 94, 133-9.
18. Hecht J L, Aster J C (2000). Molecular biology of Burkitt's lymphoma. J Clin Oncol, 18, 3707-21.
19. Hijiya N, Metzger M L, Pounds S, et al. (2005). Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatr Blood Cancer, 44, 63-9.
20. Hochberg J, Cairo M S (2008). Tumor lysis syndrome: current perspective. Haematologica, 93, 67-74.
21. Hogan D K, Rosenthal L D (1998). Oncologic emergencies in the patient with lymphoma. Semin Oncol Nurs, 14, 312-20.
22. Jeha S (2001). Tumor lysis syndrome. Semin Hematol, 38, 4-8.
23. Kadar N, Krumerman M (1995). Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor). Gynecol Oncol, 59, 394-7.
24. Klinenberg J R, Goldfinger S, Seegmiller J E (1965). The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med, 62, 639-47.
25. Klinenberg J R, Kippen I, Bluestone R (1975). Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition. Nephron, 14, 88-98.
26. Krakoff I H, Meyer R L (1965). Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA, 193, 1-6.
27. Lawrence J (1994). Critical care issues in the patient with hematologic malignancy. Semin Oncol Nurs, 10, 198-207.
28. Landgrebe A R, Nyhan W L, Coleman M (1975). Urinary-tract stones resulting from the excretion of oxypurinol. N Engl J Med, 292, 626-7.
29. Levine A M (2002). Challenges in the management of Burkitt's lymphoma. Clin Lymphoma, 3, 19-25.
30. Lorigan P C, Woodings P L, Morgenstern G R, Scarffe J H (1996). Tumour lysis syndrome, case report and review of the literature. Ann Oncol, 7, 631-6.
31. Mahmoud H H, Leverger G, Patte C, Harvey E, Lascombes F (1998). Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer, 77, 18-20.
32. Mandal A K (1997). Hypokalemia and hyperkalemia. Med Clin North Am, 81, 611-39.
33. Mayne N, Keady S, Thacker M (2008). Rasburicase in the prevention and treatment of tumour lysis syndrome. Intensive Crit Care Nurs, 24, 59-62.
34. Monbalyu J, Zachee P, Verberckmoes R, Boogaerts MA (1984). Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt's lymphoma. Clin, Nephrol, 22, 47-50.
35. Montesinos P, Lorenzo I, Martín G, et al. (2008). Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica, 93, 67-74.
36. Nakamura M, Oda S, Sadahiro T, et al. (2009). The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Transfus Apher Sci, 40, 41-7.
37. Navolanic P M, Pui C H, Larson R A, et al. (2003). Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia, 17, 499-514.
38. Oda M, Satta Y, Takenaka O, Takahata N (2002). Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol, 19, 640-53.
39. Overgaard K, Nielsen O B, Clausen T (1997). Effects of reduced electrochemical Na+ gradient on contractility in skeletal muscle: role of the Na+-K+ pump. Pflugers Arch, 434, 457-65.
40. Pak C Y (1969). Physicochemical basis for formation of renal stones of calcium phosphate origin: calculation of the degree of saturation of urine with respect to brushite. J Clin Invest, 48, 1914-22.
41. Patte C, Sakiroglu C, Ansoborlo S, et al. (2002). Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol, 13, 789-95.
42. Razis E, Arlin Z, Ahmed T (1994). Incidence and treatment of tumour lysis syndrome in patients with acute leukaemia. Acta Haematol, 91, 171-4.
43. Ribeiro R C, Pui C H (2002). Hyperuricemia in patients with cancer. Am J Cancer, 1, 409-22.
44. Rieselbach R E, Bentzel C J, Cotlove E, et al. (1964). Uric acid excretion and renal function in the acute hyperuricemia of leukemia: pathogenesis and therapy of uric acid nephropathy. Am J Med, 37, 872-83.
45. Spector T (1977). Inhibition of urate production by allopurinol. Biochem. Pharmacol, 26, 355-8.
46. Soares M, Feres G A, Salluh J I (2009). Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics (Sao Paulo), 64, 479-81.
47. Stapleton F B, Strother D R, Roy S, et al. (1988). Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics, 82, 863-9.
48. Tannock I (1978). Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep, 62, 1117-33.
49. Tsokos G C, Balow J E, Spiegel R J, Magrath I T (1981). Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore), 60, 218-29.
50. Veenstra J, Krediet R T, Somers R, Arisz L (1994). Tumour lysis syndrome and acute renal failure in Burkitt's lymphoma. Description of 2 cases and a review of the literature on prevention and management. Neth J Med, 45, 211-6.
51. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A (2003). Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urateoxidase. Ann Hematol, 82, 160-5.
52. Wilcox W R, Khalaf A, Weinberger A, Kippen I, Klinenberg J R (1972). Solubility of uric acid and monosodium urate. Med Biol Eng, 10, 522-31.
53. Yarpuzlu A A (2003). A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta, 333, 13-8.
54. Zojer N, Ludwig H (2007). Hematological emergencies. Ann Oncol, 18, 45-8.